SS-31 (Elamipretida) vs MOTS-c
SS-31 (Elamipretida) is mainly studied for cellular energy, longevity, recovery. while MOTS-c is studied for metabolic efficiency, energy, body composition. The difference is in the mechanism and the evidence, not in which is "better": it depends on the goal.
| SS-31 (Elamipretida) | MOTS-c | |
|---|---|---|
| Category | Longevity/Cellular | Metabolic |
| Studied for | Cellular energy, longevity, recovery. | Metabolic efficiency, energy, body composition. |
| How it acts | A peptide studied for its relationship with mitochondrial function and protection against oxidative stress at the cellular level. | A mitochondrial-derived peptide studied for its relationship with metabolic efficiency, glucose homeostasis and cellular-energy signaling. |
| Evidence level | Human trials available | Limited human evidence |
How they differ
Although sometimes mentioned together, SS-31 (Elamipretida) and MOTS-c do not target the same thing. SS-31 (Elamipretida): A peptide studied for its relationship with mitochondrial function and protection against oxidative stress at the cellular level. MOTS-c: A mitochondrial-derived peptide studied for its relationship with metabolic efficiency, glucose homeostasis and cellular-energy signaling.
See full entry: SS-31 (Elamipretida) → · See full entry: MOTS-c →
Want to truly understand it, not memorize it?
The course explains each peptide at a university level: how it acts, what outcomes are studied, what it combines with and when to pause. No doses: the protocol is defined by a professional.
See the course → Start with the free test →Frequently asked questions
What is the main difference between SS-31 (Elamipretida) and MOTS-c?
SS-31 (Elamipretida) targets cellular energy, longevity, recovery. and MOTS-c targets metabolic efficiency, energy, body composition. They act through different pathways, so the choice depends on your goal, not on which is "stronger".
Can they be studied together?
Combinations are studied by goal in the literature, but combining is not just adding: it changes the safety profile. What to combine and how is decided with a professional; here we only explain what each is studied for.
Which has more human evidence?
Based on the references we verified, SS-31 (Elamipretida) has more human studies of this pair. Each one's evidence level is in the table above, and the references with their PMID are at the end.
Other comparisons
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for SS-31 (Elamipretida) vs MOTS-c or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
References
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trialhuman Neurology · 2023 · PMID 37268435 →
- A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolismhuman Genet Med · 2021 · PMID 33077895 →
- Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWERhuman Genet Med · 2024 · PMID 38602181 →
- Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathyhuman Neurology · 2018 · PMID 29500292 →
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistancepreclinical Cell Metab · 2015 · PMID 25738459 →
- The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stresspreclinical Cell Metab · 2018 · PMID 29983246 →
- Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humanshuman J Appl Physiol (1985) · 2021 · PMID 34351816 →
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitationreview Front Endocrinol (Lausanne) · 2023 · PMID 36761202 →
Educational content. It does not include doses, protocols or preparation: that is defined by a professional.